Protonix News and Research

RSS

Teva signs definitive agreement to acquire Taiyo

Teva Pharmaceutical Industries Ltd. announced today that it has signed a definitive agreement to acquire 57% of the shares in privately-held Taiyo Pharmaceutical Industry Co. Ltd. for $460 million in cash paid to private shareholders.

16 May 2011

Teva signs definitive agreement to acquire Cephalon shares for $6.8 billion

Teva Pharmaceutical Industries Ltd. and Cephalon, Inc. today announced that their Boards of Directors have unanimously approved a definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The transaction is not conditioned on financing and is expected to be completed in the third quarter of 2011.

2 May 2011

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva Pharmaceutical Industries Ltd. today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system products.

12 Apr 2011

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study of laquinimod, an oral, once-daily, investigational immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). These data will be presented as late-breaking research at the Annual Meeting of the American Academy of Neurology (AAN).

12 Apr 2011

OncoGenex, Teva's custirsen preclinical data in CRPC presented at AACR meeting

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that new preclinical data of their investigational compound custirsen in castrate resistant prostate cancer were presented this week at the 102nd Annual Meeting of the AACR.

7 Apr 2011

P&G, Teva sign partnership agreement for consumer health care

The Procter & Gamble Company and Teva Pharmaceutical Industries Ltd. today announced the signing of a master agreement to create a partnership in consumer health care by bringing together both companies' existing over-the-counter medicines and complementary capabilities to accelerate growth.

25 Mar 2011

Survey: AR symptoms continue to impact patients' daily activities

Results from a recent pivotal allergic rhinitis satisfaction survey assessing patient and healthcare provider perspectives on AR reveal that symptoms like nasal congestion and post-nasal drip continue to impact patients' daily activities.

22 Mar 2011

EMA CHMP adopts positive opinion for Teva's NOMAC-E2 contraceptive pill

Teva Pharmaceutical Industries Ltd. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for NOMAC-E2, an investigational contraceptive pill combining 1.5 mg of 17-beta-estradiol with 2.5 mg of nomegestrol acetate in a 24/4 monophasic regimen.

18 Mar 2011

Trial date set for Teva's generic COPAXONE patent infringement litigation against Momenta

Teva Pharmaceutical Industries Ltd. today announced that the United States District Court for the Southern District of New York has set a trial date of September 7, 2011 in the Company's ongoing patent infringement litigation against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Pharmaceuticals, Inc./Mylan Inc./Natco Pharma Ltd. regarding their purported generic versions of COPAXONE® (glatiramer acetate injection).

2 Mar 2011

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE™ (beclomethasone dipropionate [BDP]) HFA, its nasal aerosol corticosteroid in development for the treatment of perennial allergic rhinitis (PAR) and seasonal allergic rhinitis (SAR).

10 Feb 2011

FDA grants Actavis marketing approval for Pantoprazole Sodium Delayed-Release Tablets

Actavis Group, an international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Pantoprazole Sodium Delayed-Release Tablets, USP.

9 Feb 2011

Teva fourth quarter net sales increase 16% to record $4.4 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter and year ended December 31, 2010.

8 Feb 2011

Teva announces acquisition of Corporación Infarmasa

Teva Pharmaceutical Industries Ltd. announced today the acquisition of Corporación Infarmasa, a top ten pharmaceutical company in Perú, from The Rohatyn Group and Altra Investments.

27 Jan 2011

Teva, APP enter agreement for launch of generic Gemzar

Teva Pharmaceutical Industries Ltd. and APP Pharmaceuticals, Inc. announced today the commercial launch of Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials, the generic version of Gemzar®, in the United States, pursuant to a commercialization, manufacture and supply agreement signed by the two companies.

26 Jan 2011

FDA approves Matrix's generic Protonix DR Tablets ANDA

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pantoprazole Sodium Delayed-release (DR) Tablets USP, 20 mg (base) and 40 mg (base), the generic version of Wyeth's Protonix® DR Tablets, a treatment for the irritation of the esophagus caused by gastroesophageal reflux disease (GERD).

25 Jan 2011

Teva Pharmaceutical announces entry into new three-year credit facility

Teva Pharmaceutical Industries Ltd. announced today that it has entered into a new three-year, $1.5 billion unsecured revolving credit facility, which replaces and expands existing credit lines at terms that are more favorable to Teva.

24 Jan 2011

Teva acquires Théramex

Teva Pharmaceutical Industries Ltd. announced today that it has completed the acquisition of Théramex, Merck KGaA's European-based women's health business.

5 Jan 2011

Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA

Teva Pharmaceutical Industries Ltd. announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for a lower-volume (0.5mL) injection of glatiramer acetate. Copaxone® containing 20mg of glatiramer acetate in 1ml is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS).

24 Dec 2010

Intellipharmaceutics announces delay of patent approvement to market Protonix drug

Intellipharmaceutics International, today announced that it has notified the U.S. Food and Drug Administration that it has not received notification, as provided for under the Hatch-Waxman Act, of any patent infringement proceedings by the brand owner, Wyeth Pharmaceuticals, a wholly-owned subsidiary of Pfizer, for its application to market a generic of Wyeth's Protonix® tablets.

22 Dec 2010

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.

9 Dec 2010